According to an article on The National Law Review, AI-driven drug discovery is significantly impacting pharmaceutical patent strategies. The review highlights nine leading companies that utilize AI to design and advance drug candidates. Key trends include the protection of both AI/machine learning technologies and conventional drug compositions. The analysis underscores the importance of aligning patent filings with commercial priorities and targets, with companies leveraging AI to enhance drug development and maintain competitive advantage. This evolving landscape presents opportunities for strategic partnerships and robust IP protection.